Rafferty Asset Management
PCRX icon

Rafferty Asset Management’s Pacira BioSciences PCRX Stock Holding History

Rafferty Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
+8,481
New +$200K ﹤0.01% 1084
2026
Q1 		– Sell
-9,285
Closed -$240K – 1124
2025
Q4 		$240K Buy
+9,285
New +$221K ﹤0.01% 1039
2025
Q2 		– Sell
-10,092
Closed -$251K – 1097
2025
Q1 		$251K Buy
+10,092
New +$242K ﹤0.01% 998
2024
Q4 		– Sell
-14,847
Closed -$223K – 1167
2024
Q3 		$223K Buy
14,847
+7,423
+100% +$127K ﹤0.01% 1087
2024
Q2 		$212K Buy
+7,424
New +$211K ﹤0.01% 1122
2024
Q1 		– Sell
-6,217
Closed -$210K – 1092
2023
Q4 		$210K Buy
+6,217
New +$182K ﹤0.01% 1058
2022
Q4 		– Sell
-4,404
Closed -$234K – 1145
2022
Q3 		$234K Buy
4,404
+154
+4% +$8.56K ﹤0.01% 1064
2022
Q2 		$248K Buy
4,250
+5
+0.1% +$328 ﹤0.01% 990
2022
Q1 		$324K Sell
4,245
-3,209
-43% -$214K ﹤0.01% 1091
2021
Q4 		$449K Buy
7,454
+312
+4% +$17.2K ﹤0.01% 1082
2021
Q3 		$400K Buy
7,142
+1,735
+32% +$100K ﹤0.01% 1095
2021
Q2 		$328K Buy
5,407
+867
+19% +$54.9K ﹤0.01% 1157
2021
Q1 		$318K Sell
4,540
-1,812
-29% -$129K ﹤0.01% 1066
2020
Q4 		$380K Buy
6,352
+1,133
+22% +$66.3K ﹤0.01% 751
2020
Q3 		$314K Buy
5,219
+642
+14% +$37.3K ﹤0.01% 798
2020
Q2 		$240K Buy
+4,577
New +$191K ﹤0.01% 878
2020
Q1 		– Sell
-4,908
Closed -$222K – 752
2019
Q4 		$222K Sell
4,908
-3,794
-44% -$161K ﹤0.01% 827
2019
Q3 		$331K Buy
8,702
+2,951
+51% +$118K 0.01% 736
2019
Q2 		$250K Buy
+5,751
New +$244K ﹤0.01% 761
2015
Q1 		– Sell
-5,331
Closed -$473K – 579
2014
Q4 		$473K Buy
+5,331
New +$504K 0.11% 241

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's PCRX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 8,481 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #1084 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in PCRX as recently as Q4 2025.

Rafferty Asset Management first reported a position in PCRX in Q4 2014 and has held it in 20 quarters since. The position peaked at $473K in Q4 2014. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Rafferty Asset Management held 8,481 shares of Pacira BioSciences worth $215K as of Q2 2026.
  • Pacira BioSciences was a new Rafferty Asset Management position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1084 holding.
  • Rafferty Asset Management first reported a position in Pacira BioSciences in Q4 2014 and has held it in 20 quarters since.
  • Rafferty Asset Management's Pacira BioSciences position peaked at $473K in Q4 2014.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.